KR20060082037A - 퀘티아핀의 대사산물 - Google Patents

퀘티아핀의 대사산물 Download PDF

Info

Publication number
KR20060082037A
KR20060082037A KR1020057025264A KR20057025264A KR20060082037A KR 20060082037 A KR20060082037 A KR 20060082037A KR 1020057025264 A KR1020057025264 A KR 1020057025264A KR 20057025264 A KR20057025264 A KR 20057025264A KR 20060082037 A KR20060082037 A KR 20060082037A
Authority
KR
South Korea
Prior art keywords
disorders
bipolar
symptoms
depression
anxiety
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
KR1020057025264A
Other languages
English (en)
Korean (ko)
Inventor
제프리 골드스테인
스콧 더블유. 그림
헬렌 알. 윈터
패트리샤 씨. 데이비스
레이몬드 에프. 수코우
Original Assignee
아스트라제네카 아베
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 아스트라제네카 아베 filed Critical 아스트라제네카 아베
Publication of KR20060082037A publication Critical patent/KR20060082037A/ko
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/554—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
KR1020057025264A 2003-07-02 2004-06-28 퀘티아핀의 대사산물 Withdrawn KR20060082037A (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US48436503P 2003-07-02 2003-07-02
US60/484,365 2003-07-02

Publications (1)

Publication Number Publication Date
KR20060082037A true KR20060082037A (ko) 2006-07-14

Family

ID=33563981

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020057025264A Withdrawn KR20060082037A (ko) 2003-07-02 2004-06-28 퀘티아핀의 대사산물

Country Status (20)

Country Link
US (1) US20050026900A1 (enExample)
EP (1) EP1644005B1 (enExample)
JP (1) JP2007516193A (enExample)
KR (1) KR20060082037A (enExample)
CN (1) CN1816339B (enExample)
AR (1) AR045004A1 (enExample)
AT (1) ATE477803T1 (enExample)
AU (1) AU2004253334A1 (enExample)
BR (1) BRPI0412127A (enExample)
CA (1) CA2531284A1 (enExample)
DE (1) DE602004028739D1 (enExample)
ES (1) ES2349091T3 (enExample)
IL (1) IL172616A0 (enExample)
IS (1) IS8283A (enExample)
MX (1) MXPA05013869A (enExample)
NO (1) NO20060556L (enExample)
RU (1) RU2005141060A (enExample)
TW (1) TW200509944A (enExample)
UY (1) UY28400A1 (enExample)
WO (1) WO2005002586A1 (enExample)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2479668A1 (en) * 2002-03-20 2003-10-02 Teva Pharmaceutical Industries Ltd. Crystalline forms of quetiapine hemifumarate
WO2008021463A2 (en) * 2006-08-15 2008-02-21 Acadia Pharmaceuticals, Inc. Amino substituted diaryl[a,d]cycloheptene analogs as muscarinic agonists and methods of treatment of neuropsychiatric disorders
NZ547911A (en) 2003-12-22 2010-06-25 Acadia Pharm Inc Amino substituted diaryl[a,d]cycloheptene analogs as muscarinic agonists and methods of treatment of neuropsychiatric disorders
US20060081361A1 (en) * 2004-09-13 2006-04-20 Gabbey Lawrence W Oil cooler with integral filter
EP1838325A1 (en) * 2005-01-07 2007-10-03 AstraZeneca AB NEW USE OF 11-PIPERAZIN-1-YLDIBENZO [b,f][1,4]THIAZEPINE OR ITS PHARMACEUTICALLY ACCEPTABLE SALT AND TO ORAL PHARMACEUTICAL COMPOSITIONS
AU2006231497A1 (en) * 2005-04-04 2006-10-12 Acadia Pharmaceuticals Inc. Use of N-desmethylclozapine and related compounds as dopamine stabilizing agents
JP2008502707A (ja) * 2005-04-14 2008-01-31 テバ ファーマシューティカル インダストリーズ リミティド クエチアピンフマレートの調製方法
WO2007004234A1 (en) * 2005-07-04 2007-01-11 Usv Limited A PROCESS FOR THE PREPARATION OF 2-[2-(4-DIBENZO[b,f] [L,4] THIAZEPIN-11-yl-1- PIPERAZINYL)ETHOXY] ETHANOL FUMARATE
JP2009516706A (ja) * 2005-11-18 2009-04-23 アストラゼネカ・アクチエボラーグ 結晶形
WO2008079839A1 (en) * 2006-12-20 2008-07-03 Astrazeneca Ab Compounds and uses thereof
JP2009516707A (ja) * 2005-11-18 2009-04-23 アストラゼネカ・アクチエボラーグ 固形製剤
US8389510B2 (en) 2005-11-18 2013-03-05 Astrazeneca Ab Crystalline forms
US20090069292A1 (en) * 2005-11-18 2009-03-12 Astrazeneca Ab Liquid Formulations
JP2009516705A (ja) * 2005-11-18 2009-04-23 アストラゼネカ・アクチエボラーグ 塩の形態
WO2008118141A2 (en) * 2006-10-17 2008-10-02 Acadia Pharmaceuticals Inc. Use of cannabinoid modulating compounds in combination with other therapeutic compounds for adjunctive therapy
JP2010514684A (ja) * 2006-12-20 2010-05-06 アストラゼネカ・アクチエボラーグ 化合物及びその使用
CN101616585A (zh) * 2006-12-20 2009-12-30 阿斯利康(瑞典)有限公司 化合物及其用途
JP2010522211A (ja) * 2007-03-22 2010-07-01 アストラゼネカ・アクチエボラーグ 気分障害を治療する方法
CN104586859B (zh) * 2009-12-31 2017-12-05 凯姆制药公司 喹硫平的氨基酸缀合物、其制备和使用方法
DK2544536T3 (en) 2010-03-11 2019-02-04 Kempharm Inc FAT ACID CONJUGATES OF QUETIAPIN, METHOD OF PREPARING IT AND USING IT
CN102552128B (zh) * 2012-02-28 2013-09-18 陆荣政 一种富马酸喹硫平注射液及其制备方法
US9993486B1 (en) 2017-06-19 2018-06-12 Tlc Therapeutics, Llc Oral quetiapine suspension formulations with extended shelf life and enhanced bioavailability

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL140242B (nl) * 1963-03-01 1973-11-15 Wander Ag Dr A Werkwijze voor het bereiden van op de 11-plaats door een basische groep gesubstitueerde dibenz (b.f.)(1.4) oxazepinen.
GB1192812A (en) * 1966-05-20 1970-05-20 American Cyanamid Co 2-Chloro-11-(1-Piperazinyl)Dibenz[b,f]-[1,4]Oxazepine, Non-Toxic Acid Addition Salts thereof, and Therapeutic Compositions containing said Oxazepine or Salts
US3539573A (en) * 1967-03-22 1970-11-10 Jean Schmutz 11-basic substituted dibenzodiazepines and dibenzothiazepines
US3966949A (en) * 1973-10-12 1976-06-29 Richardson-Merrell Inc. Pharmaceutical compositions and preparing same
GB8607684D0 (en) * 1986-03-27 1986-04-30 Ici America Inc Thiazepine compounds
US5750566A (en) * 1994-08-12 1998-05-12 Eli Lilly And Company Synthetic excitatory amino acids
US6342488B1 (en) * 1998-08-18 2002-01-29 Sepracor, Inc. Phosphonorisperidone and sulforisperidone compositions and methods
WO2004064753A2 (en) * 2003-01-23 2004-08-05 Acadia Pharmaceuticals Inc Use of n-desmethylclozapine to treat human neuropsychiatric disease

Also Published As

Publication number Publication date
WO2005002586A8 (en) 2006-02-09
IS8283A (is) 2006-02-01
UY28400A1 (es) 2005-01-31
IL172616A0 (en) 2006-04-10
AR045004A1 (es) 2005-10-12
AU2004253334A1 (en) 2005-01-13
JP2007516193A (ja) 2007-06-21
BRPI0412127A (pt) 2006-08-15
ATE477803T1 (de) 2010-09-15
NO20060556L (no) 2006-04-03
ES2349091T3 (es) 2010-12-27
TW200509944A (en) 2005-03-16
EP1644005A1 (en) 2006-04-12
CA2531284A1 (en) 2005-01-13
EP1644005B1 (en) 2010-08-18
WO2005002586A1 (en) 2005-01-13
DE602004028739D1 (de) 2010-09-30
RU2005141060A (ru) 2006-07-27
CN1816339A (zh) 2006-08-09
CN1816339B (zh) 2010-12-15
MXPA05013869A (es) 2006-02-28
US20050026900A1 (en) 2005-02-03

Similar Documents

Publication Publication Date Title
KR20060082037A (ko) 퀘티아핀의 대사산물
JP2008525414A (ja) 精神病性障害を治療するためのサブコメリンと神経遮断薬との組み合わせ
US20110136786A1 (en) Method of treating mood disorders
US20110144089A1 (en) Method of treating schizophrenia and other disorders
KR20050121235A (ko) 정동 장애를 치료하기 위한10-히드록시-10,11-디히드로카르바마제핀 유도체의 용도
TW201144321A (en) Benzazepine compound
US20110136784A1 (en) Method of Treating Anxiety Disorders
KR20050121236A (ko) 치매 환자에서 초조 증상을 치료하기 위한 카르바마제핀유도체의 용도
US20050026899A1 (en) Metabolite
US20090093461A1 (en) Methods of Treating Anxiety and Mood Disorders
US20090093460A1 (en) Compositions
CA2415475C (en) Pyrrolo[2,1-b][1,3]benzothiazepines and their use for the preparation of medicaments with antipsychotic activity
US20110144088A1 (en) Method of treating sleep disorders
US20100093700A1 (en) Methods of Treating Mood Disorders
JP2008526839A (ja) １１−ピペラジン−１−イルジベンゾ［ｂ，ｆ］［１，４］チアゼピン又はその薬学的に許容される塩の新規な使用及び経口医薬組成物への新規な使用
US20110136785A1 (en) Method of treatment
AU2001284391A1 (en) Pyrrolo[2,1-b][1,3]benzothiazepines and their use for the preparation of medicaments with antipsychotic activity
CN101351210A (zh) 11－哌嗪－1－基二苯并[b,f][l,4]硫氮杂卓或其药学上可接受的盐的新用途及其用于口服药物组合物的新用途
EP3322422A1 (en) Heteroaryl carbonitriles for the treatment of disease
US20060229292A1 (en) Method of treating childhood disorders

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20051229

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
PC1203 Withdrawal of no request for examination
WITN Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid